RxDoctor Payments Data

Kyle McCoy, MD

Cardiovascular Disease · Powell, TNNPI 1053301622

Payments from drug & device makers

$1,702in general payments, 2019–2025

Across 95 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$528
  • Novartis$510
  • Johnson & Johnson$157
  • Pfizer$134
  • Boston Scientific$59
  • Atricure, Inc.$48
  • plus $266 from 11 others

What the payments were for

  • Food & beverage$1,66198%
  • Education$412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,702 in reported general payments places this provider in the 40th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$177,721
Medicare patients
687
Services billed
2,683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban951$794,510
XareltoRivaroxaban480$464,211
Repatha SureclickEvolocumab197$147,872
EntrestoSacubitril/Valsartan121$101,247
JardianceEmpagliflozin25$18,407
FarxigaDapagliflozin Propanediol16$14,277
Dabigatran EtexilateDabigatran Etexilate Mesylate39$13,582
Repatha SyringeEvolocumab17$9,715
Diltiazem 24hr Er (Cd)Diltiazem Hcl483$8,978
Praluent PenAlirocumab17$8,140
Flecainide Acetate216$7,793
Rosuvastatin Calcium673$5,868
Metoprolol Succinate508$5,000
Ezetimibe327$4,795
Ranolazine ErRanolazine73$4,769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$134$794,510951 claims
Johnson & JohnsonXarelto$157$464,211480 claims
NovartisEntresto$510$101,247121 claims
AstraZenecaFarxiga$23$14,27716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Powell

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →